Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIMDAX in Acute Decompensated Heart Failure (Korea Bridging Study)
NCT03555123Phase 3Unknown
- Sponsor
- Yooyoung Pharmaceutical
- Start
- Jan 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute decompensated heart failure (ADHF) comparing SIMDAX with SIMDAX Placebo (2 arms). Primary endpoint: Clinical Composite Classification (Improved, No change, Worse) at 5 days. Status: unknown.
02
Drugs
levosimendan
03
Conditions
acute decompensated heart failure (ADHF)
Beyond the preview
Go deeper on NCT03555123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03555123.